Collectively, these data highlighted the unexpected and differential effect of donor CP on modulating endogenous SARS-CoV-2 antibody evolution, resulting in both pro- and anti-inflammatory effects depending on pre-existing antibody levels in patients with severe COVID-19. This evidence concerns the gene CP and COVID-19.